Saturday, March 15, 2025
4.4 C
London
HomeFinTechPrescient Therapeutics: Signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics: Signs new research agreement with Peter MacCallum Cancer Centre

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic ShiftHighlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...
  • Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs
  • CAR-T is a type of cellular therapy that reprograms the immune cells of cancer patients to recognise and destroy cancerous cells
  • PTX has an existing research agreement with Peter Mac focusing on cell therapy enhancement programs, which also looks to improve the current CAR-T approaches
  • This new agreement extends the relationship between the parties to include the development of the OmniCAR platform
  • Under the terms of the research agreement, PTX will also have access to the expertise and facilities of Peter Mac
  • On the market today, PTX is up 1.12 per cent, trading at 9 cents per share

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories